| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Bernard Escudier | Q54553923 |
| P2093 | author name string | Hatem A Azim | |
| Hamdy Azim | |||
| P433 | issue | 7 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 633-638 | |
| P577 | publication date | 2009-07-28 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Trastuzumab versus lapatinib: the cardiac side of the story | |
| P478 | volume | 35 |
| Q91792457 | Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity |
| Q39689222 | Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q54489633 | Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms?. |
| Q48212195 | Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. |
| Q33352155 | Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors |
| Q39303131 | Cardio-oncology in the older adult. |
| Q33573823 | Cardiomyocyte autophagy and cancer chemotherapy |
| Q45073135 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. |
| Q55222160 | Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. |
| Q97530560 | Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model |
| Q30593372 | Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes |
| Q38137648 | Influence of mitochondrion-toxic agents on the cardiovascular system |
| Q38845457 | Late Cardiotoxicity: Issues for Childhood Cancer Survivors |
| Q89993252 | Personalized Approach to Cancer Treatment-Related Cardiomyopathy |
| Q37785387 | Prevention and management of major side effects of targeted agents in breast cancer |
| Q37205811 | Targeting the human epidermal growth factor receptor 2 pathway in breast cancer |
| Q61446600 | Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
| Q30402943 | Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) to Monitor Compound Effects on Cardiac Myocyte Signaling Pathways |
Search more.